-
Antidepressant TOP10 reshuffle Green leaf class 1 new drugs are eye-catching
Time of Update: 2022-10-31
0 China Drug Evaluation Database Since the beginning of this year, 6 varieties (27 specifications) of antidepressants have been approved for marketing, among which escitalopram oxalate tablets, mirtazapine tablets, venlafaxine hydrochloride sustained-release capsules, and duloxetine hydrochloride enteric-coated capsules are the terminal TOP10 products in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) in the first half of 2022.
-
2022 SHS| Professor Huang Haiwen: Strive for the best of good, explore the optimization strategy of autologous hematopoietic stem cell transplantation, analyze the characteristic clinical diagnosis
Time of Update: 2022-10-26
On this occasion, Yimaitong specially invited Professor Huang Haiwen from the First Affiliated Hospital of Soochow University to interpret the application status and future prospects of autologous hematopoietic stem cell transplantation in lymphoma based on clinical experience, so as to feed readers!
-
CheckMate-649 study data update, how do you think about "all patients benefit
Time of Update: 2022-06-07
Based on the CheckMate-649 study, the clinical treatment of advanced gastric cancer has made a breakthrough from chemotherapy alone to combined chemoimmunotherapy .
pdf[2] Yelena Y Janjigian, Kohei Shitara, Markus Moehler ,et al.
-
Professor Lu Shun led the severtinib study on the international academic stage for the third time, bringing super long-term survival data
Time of Update: 2022-04-27
The Phase II clinical study of sevolitinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation, led by Professor Lu Shun of the Chest Hospital Affiliated to Shanghai Jiaotong University, was successfully selected for the 2022 ELCC oral report.
-
Delta strain is prevalent, how effective is the new crown vaccine booster
Time of Update: 2021-11-15
Based on data analysis of more than one million people across Israel, compared with only two shots and completed vaccination for at least 5 months, the third shot of BNT162b2 mRNA new crown vaccine reduces the risk of new crown infection, hospitalization and severe illness by about 90%.
-
China Food and Drug Administration: Thermo Fisher Scientific and Rejuvenation Medical Devices are recalling a batch of medical devices
Time of Update: 2021-09-19
actively recalled the disposable blood transfusion set with needlesChangzhou Huichun Medical Equipment Co.
reported that the disposable blood transfusion set with needles produced by this company has leaked, and it is now actively recalled.
-
Health Commission: Support for traceability in many countries, including the United States
Time of Update: 2021-09-10
National Health Commission: Supporting traceability research in many countries and places around the world, including the United States National Health and Medical Commission: Suppo
-
Taking stock of the report on the financing trends of the healthcare industry in the first half of the year, where did all the money in the venture capital circle go
Time of Update: 2021-08-10
Source: Flint Creation Database [Distribution of financing amount] A total of 578 projects received investment from January to June, with a cumulative amount exceeding 115.
-
Different types of "jaundice", one picture teaches you to distinguish
Time of Update: 2021-06-17
The etiology of bilirubin has been broadly defined, which is helpful for diagnosis and treatment.
According to the etiology, it is divided into hemolytic jaundice, hepatocellular jaundice, cholestatic jaundice, and congenital non-hemolytic jaundice.
-
Blockbuster therapy allows early-stage lung cancer patients to "survive without cancer" longer, and it has been launched in China
Time of Update: 2021-04-28
▎Editor of WuXi AppTec's content team On March 22, Genentech, a subsidiary of Roche, announced that its PD-L1 antibody Tecentriq (atezolizumab, atezolizumab) is in the treatment of early stage non-small cell lung cancer NSCLC) patients reached the primary endpoint in a phase 3 clinical trial.
-
A large number of pharmaceutical representatives turned to the grass-roots market
Time of Update: 2021-02-20
He gave an example: a foreign company's pharmaceutical representative, the basic salary at least 4000-5000 yuan, coupled with social security expenditure, labor costs are relatively high, and foreign companies' drug prices were generally too expensive before, taking into account the county market patients' ability to pay, the county hospital's foreign drug prescription volume is also very limited, in general, foreign enterprises sinking the grass-roots cost-effective.
-
The General Administration issued the 5th National Medical Device Quality Bulletin 2016
Time of Update: 2021-02-08
The State Administration of Food and Drug Administration announced the 5th issue of the 2016 National Medical Device Quality Bulletin, which announced the supervision and testing of the quality of 463 batches (Taiwan) of 6 varieties of products, such as gravity infusion type (with needle), TCM medical and therapeutic electrical equipment, and continuous blood purification equipment.
(State Administration of Food and Drug Administration)
-
Domestic giants are gnawing at the lack of core technology for high-end medical devices
Time of Update: 2021-02-07
Domestic high-end medical device market is now beginning to enter the development period, core technology and after-sales service is still the focus of medical institutions, but also domestic enterprises need to overcome the difficulties.
-
Take stock of the national medical supplies with the volume of procurement "progress bar
Time of Update: 2020-10-29
Recently, the industry's hotly debated volume procurement topic has undoubtedly been pushed to a climax. incomplete statistics, so far, the country has completed a total of 11 provincial and 4 provi
-
Ping An Good Doctor was sued by Good Doctor Pharmaceuticals for $70 million in assets frozen by the court
Time of Update: 2020-10-08
(later referred to as Good Doctor Pharmaceuticals), Sichuan Good Doctor Panxi Pharmaceutical Limited Public Liability Company (later: Sichuan Good Doctor) and Ping An Health Unfair Competition Dispute, the case of the applicant Good Doctor Pharmaceuticals On July 28, 2020, Dr. Sichuan Good applied to the Intermediate People's Court of Liangshan Yi Autonomous Prefecture, Sichuan Province, for property preservation, requesting the preservation of 90,000,000.00 yuan or other assets of equivalent value of Ping An Health Cash.
